Register for free to
view the full innovation profile.
Effective in triple negative cancer; first in class technology indicating novel pathway
About
Hystone lysine methyltranferases (HKMT) are targets implicated in cancer and cancer stem cell maintenance. We have filed patents for a series of small molecule dual inhibitors of HKMTs (namely EZH2 and G9a). These small molecules have been identified using a novel phenotypic assay of triple negative breast cancer and indicate a novel mechanism of action. This technology is available for co-development or licensing from Innovations. When contacting us, please use our internal reference code:5988